World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
51767
World Ranking
8434
National Ranking
4360

Eric Lawitz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eric Lawitz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 543 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Eric Lawitz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eric Lawitz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Eric Lawitz is affiliated with The University of Texas at Austin in the United States. Their research primarily focuses on medicine, with an emphasis on hepatology, epidemiology, surgery, endocrinology, diabetes and metabolism, and oncology.

The scientist has contributed extensively to the study of liver-related diseases and conditions. Key research areas include liver disease diagnosis and treatment, liver diseases and immunity, liver disease and transplantation, hepatitis C virus research, diet, metabolism and disease, pancreatitis pathology and treatment, and gallbladder and bile duct disorders.

Eric Lawitz has published frequently in several prominent medical journals. The main publication venues include:

  • Journal of Hepatology
  • The American Journal of Gastroenterology
  • Gastroenterology
  • Hepatology
  • The Lancet Gastroenterology & Hepatology

Frequent co-authors with whom Lawitz has collaborated include:

  • Lisa D. Pedicone
  • Fabian Rodas
  • Carmen Landaverde
  • Eugenia Tsai
  • Naim Alkhouri

Notable recent papers authored or co-authored by Eric Lawitz include:

  • "Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis," 2024, New England Journal of Medicine
  • "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials," 2020, Journal of Hepatology
  • "Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial," 2023, The Lancet Gastroenterology & Hepatology
  • "Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial," 2020, Hepatology
  • "A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis," 2024, New England Journal of Medicine

Best Publications

  • Treatment of HCV Infection by Targeting MicroRNA

    Harry L A Janssen;Hendrik W Reesink;Eric J Lawitz;Stefan Zeuzem

  • Sofosbuvir for previously untreated chronic hepatitis C infection

    Eric Lawitz;Alessandra Mangia;David Wyles;Maribel Rodriguez-Torres

  • Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

    Bruce R. Bacon;Stuart C. Gordon;Eric Lawitz;Patrick Marcellin

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

    John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir

  • Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

    Nezam Afdhal;K. Rajender Reddy;David R. Nelson;Eric Lawitz

  • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

    Mark S. Sulkowski;David F. Gardiner;Maribel Rodriguez-Torres;K. Rajender Reddy

  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

    Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

    Eric Lawitz;Mark S Sulkowski;Reem Ghalib;Maribel Rodriguez-Torres

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

    Paul Y Kwo;Eric J Lawitz;Jonathan McCone;Eugene R Schiff

  • Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

    Alexander J. Thompson;Andrew J. Muir;Andrew J. Muir;Mark S. Sulkowski;Dongliang Ge

  • Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis

    M. P. Curry;J. G. O'Leary;N. Bzowej;A. J. Muir

  • All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

    David R. Nelson;James N. Cooper;Jacob P. Lalezari;Eric Lawitz

  • Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

    Anna S. Lok;David F. Gardiner;Eric Lawitz;Claudia Martorell

  • Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

    Eric Lawitz;Fred F Poordad;Phillip S Pang;Robert H Hyland

  • Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.

    Arun Sanyal;Edgar D Charles;Brent A Neuschwander-Tetri;Rohit Loomba

  • The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

    Rohit Loomba;Eric Lawitz;Parvez S. Mantry;Saumya Jayakumar

  • Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

    Edward Gane;Eric Lawitz;David Pugatch;Georgios Papatheodoridis

Frequent Co-Authors

Zobair M. Younossi
Zobair M. Younossi Inova Health System
Ira M. Jacobson
Ira M. Jacobson New York University
John G. McHutchison
John G. McHutchison Duke University
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Andrew J. Muir
Andrew J. Muir Duke University
Kris V. Kowdley
Kris V. Kowdley Washington State University
Mitchell L. Shiffman
Mitchell L. Shiffman Bon Secours Health System
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center
David R. Nelson
David R. Nelson University of Tennessee Health Science Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring alternative healthcare pathways beyond traditional medical school, there are several flexible online options to consider. Many aspiring healthcare professionals are looking to streamline their entry into this field, whether by bypassing certain entrance exams or advancing their credentials efficiently.

For those interested in nursing, enrolling in an lpn school without teas test can save time and reduce barriers to admission. This is an excellent choice if you want to begin your nursing career quickly.

If you aim for leadership roles, an accelerated healthcare administration degree can help fast-track your management ambitions within the healthcare industry.

Registered nurses seeking advanced practice can look into rn to fnp bridge programs that offer convenient transitions to become Family Nurse Practitioners.

For those interested in preventative medicine and wellness, earning an online degree nutrition can open doors to careers in dietetics, public health, and research.

These related online degrees offer versatile career routes in healthcare, accommodating varying interests, career stages, and educational backgrounds.

Best Scientists Citing Eric Lawitz

Trending Scientists